Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.59 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | APAF1 | O14727 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL1716467 | 1.00 | PBRM1 (0.59) | PBRM1SLC22A6GPR84KDM4EMAPT | |
| Sulfuric Acid SCHEMBL17028779 | 0.93 | PBRM1 (0.53) | PBRM1SLC22A6GPR84KDM4EMAPT | |
| Pyruvate SCHEMBL29152649 | 0.93 | PBRM1 (0.56) | PBRM1SLC22A6GPR84KDM4EMAPT | |
| Acetic Acid SCHEMBL27807549 | 0.89 | PBRM1 (0.56) | PBRM1SLC22A6GPR84KDM4EMAPT | |
| SCHEMBL29567690 | 0.88 | MEN1 (0.58) | PBRM1GPR84KDM4EMAPTMEN1 | |
| SCHEMBL155191 | 0.88 | MEN1 (0.58) | PBRM1GPR84KDM4EMAPTMEN1 | |
| Hydrochloric Acid SCHEMBL28628671 | 0.86 | MEN1 (0.56) | PBRM1GPR84KDM4EMAPTMEN1 | |
| SCHEMBL28624457 | 0.86 | MEN1 (0.56) | PBRM1GPR84KDM4EMAPTMEN1 | |
| Methane SCHEMBL5065725 | 0.86 | MEN1 (0.56) | PBRM1GPR84KDM4EMAPTMEN1 | |
| SCHEMBL10550137 | 0.86 | MEN1 (0.56) | PBRM1GPR84KDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240084002-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2024-03-14 | — | — | US | claimed |
| EP-4255423-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | Lankenau Institute for Medical Research (US) | 2023-10-11 | — | — | EP | claimed |
| US-11752131-B2 | Methods and pharmaceutical compositions for the treatment of obesity | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-09-12 | — | — | US | claimed |
| WO-2022125553-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2022-06-16 | — | — | WO | claimed |
| EP-1613308-A4 | NOVEL METHODS FOR THE TREATMENT OF CANCER | LANKENAU INST MEDICAL RES (US) | 2008-02-20 | — | — | EP | claimed |
| EP-1613308-A1 | NOVEL METHODS FOR THE TREATMENT OF CANCER | Lankenau Institute for Medical Research (US) | 2006-01-11 | — | — | EP | claimed |
| WO-2004093871-A1 | NOVEL METHODS FOR THE TREATMENT OF CANCER | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2004-11-04 | — | — | WO | claimed |
| EP-3906415-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR ENHANCING CD8+ T CELL-DEPENDENT IMMUNE RESPONSES IN SUBJECTS SUFFERING FROM CANCER | INST NAT SANTE RECH MED (FR) | 2026-04-15 | — | — | EP | disclosed |
| EP-4713371-A1 | ANTI-CATHEPSIN-D ANTIBODIES | Institut National de la Santé et de la Recherche Médicale (FR) | 2026-03-25 | — | — | EP | disclosed |
| US-20260061031-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DILATED CARDIOMYOPATHY | INST NAT SANTE RECH MED (FR) | 2026-03-05 | — | — | US | disclosed |
| EP-4689658-A1 | METHOD FOR DISCRIMINATING MONO-IMMUNOTHERAPY FROM COMBINED IMMUNOTHERAPY IN CANCERS | Institut National de la Santé et de la Recherche Médicale (FR) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035471-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR ENHANCING CD8+ T CELL-DEPENDENT IMMUNE RESPONSES IN SUBJECTS SUFFERING FROM CANCER | INST NAT SANTE RECH MED (FR) | 2026-02-05 | — | — | US | disclosed |
| WO-2025202213-A9 | LIPID NANOPARTICLE LOADED WITH ANTITUMORAL AGENT AND FUNCTIONNALIZED TO TARGET IMMOSUPPRESSIVE CELLS | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-12-26 | — | — | WO | disclosed |
| US-6512100-B1 | Yield chromogenic products after reactions catalyzed by sialidase take place, diagnosis; neuraminic acid derivatives | IBBEX, INC. | 2003-01-28 | — | — | US | disclosed |
| EP-1218390-A2 | CHROMOGENIC SUBSTRATES OF SIALIDASE OF BACTERIAL, VIRAL, PROTOZOA, AND VERTEBRATE ORIGIN AND METHODS OF MAKING AND USING THE SAME | Ibbex, Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| US-20020004219-A1 | Trypsin substrate and diganostic device, and method of using same | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2002-01-10 | — | — | US | disclosed |
| EP-1157984-A2 | Trypsin substrate and diagnostic device, and method of using same | Bayer Corporation (US) | 2001-11-28 | — | — | EP | disclosed |
| EP-1124836-A1 | CHROMOGENIC SUBSTRATES OF SIALIDASE AND METHODS OF MAKING AND USING THE SAME | Ibbex, Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2001025246-A2 | CHROMOGENIC SUBSTRATES OF SIALIDASE OF BACTERIAL, VIRAL, PROTOZOA, AND VERTEBRATE ORIGIN AND METHODS OF MAKING AND USING THE SAME | IBBEX, INC. (US) | 2001-04-12 | — | — | WO | disclosed |
| WO-2000024753-A1 | CHROMOGENIC SUBSTRATES OF SIALIDASE AND METHODS OF MAKING AND USING THE SAME | IBBEX, INC. (US) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061031-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DILATED CARDIOMYOPATHY | CD274, PDCD1, ICOS | PBRM1 990/4885SLC22A6 2499/4885GPR84 793/4885 |
| US-20020004219-A1 | Trypsin substrate and diganostic device, and method of using same | PRSS3, CTRL, PRSS2 | PBRM1 3265/4885SLC22A6 3444/4885GPR84 2255/4885 |
| US-20240084002-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | IDO1, IDO2, TIE1 | PBRM1 3718/4885SLC22A6 4454/4885GPR84 1810/4885 |
| US-11752131-B2 | Methods and pharmaceutical compositions for the treatment of obesity | IDO1, IDO2, GPR119 | PBRM1 4331/4885SLC22A6 2452/4885GPR84 1077/4885 |
| US-20260035471-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR ENHANCING CD8+ T CELL-DEPENDENT IMMUNE RESPONSES IN SUBJECTS SUFFERING FROM CANCER | CD274, PDCD1LG2, PDCD1 | PBRM1 849/4885SLC22A6 4056/4885GPR84 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.